Navigation Links
Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
Date:10/29/2013

PRINCETON, N.J., Oct. 29, 2013 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported results for its third quarter ended September 30, 2013.  Net revenue was $606.7 million, representing 11.4% growth from the third quarter of 2012's GAAP result of $544.8 million, and 12.0% growth from the third quarter of 2012's pro forma result of $541.9 million.  On a GAAP basis, the company reported earnings of $0.78 per diluted share in the third quarter of 2013 as compared to GAAP earnings of $0.69 in the third quarter of 2012.  Excluding charges associated with restructuring and other cost reduction actions totaling $4.9 million, the company reported earnings per diluted share of $0.83, up 15.8% over the pro forma earnings of $0.72 for the third quarter of 2012. 

"Financial highlights in the third quarter included consolidated pro forma revenue growth of 12%, operating margin of 11.1%, EPS of $0.83, and record quarterly free cash flow of $180 million. Our better-than-expected results in the third quarter were driven by exceptional performance in our central laboratory and continued strong results in clinical development," said Joe Herring, Chairman and Chief Executive Officer. "Strong commercial execution continued in the third quarter, as we delivered adjusted net orders of $732 million and an adjusted net book-to-bill of 1.21 to 1.  

"Late-Stage Development revenue grew 19% year-on-year to $386 million and pro forma operating margins were 22.6%, up 260 basis points from a year ago and 120 basis points from last quarter.  Better-than-expected kit volumes and a richer mix in central laboratories drove year-over-year revenue growth of 26%, while clinical development grew revenue 14% year-on-year. Both service lines expanded margins year-over-year and sequentially.

"In Early Development, revenue grew $6 million sequentially to $220 millio
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
7. Covance To Present At The Leerink Swann Global Healthcare Conference
8. Covance To Present At The Citi 2013 Global Healthcare Conference
9. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
10. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
11. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... development of drugs targeting unmet needs in oncology, autoimmune and ... 2014 Health Care Conference to be held at The New ... on September 3-4, 2014. Alan Fuhrman ... and its lead drug candidate, quizartinib, at 1:10 p.m. ET ...
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... 27, 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ... , today announced the results of the Company,s 2014 Annual ... Beijing , PRC. The required quorum, a majority ... The Company,s shareholders approved the following proposals:  , ... , Simon Anderson , Kenneth Lee and ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical and medical applications, has entered into ... Solutions Australasia Pty. Ltd., based in Newport, Victoria, ...
... Aug. 12, 2011 Southern Research Institute today announced ... named Vice President of the Drug Discovery Division. Dr. ... research and target identification and lead discovery ... diseases and neurological diseases and disorders. ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Australia and New Zealand 2Misonix Announces New Distribution Agreement for Australia and New Zealand 3Southern Research Names Mark Suto Vice President of Drug Discovery 2
(Date:8/27/2014)... August 27, 2014 Sound Telecom, a ... solutions, and cloud-based business communication systems, has unveiled an ... about HIPAA-compliant Secure Text Messaging .” The piece examines ... need to do to remain compliant with HIPAA and ... the article and C.O.O. at Sound Telecom, opens with ...
(Date:8/27/2014)... August 27, 2014 Dr. Stewart ... Center see multitudes of patients suffering from impaired vision. ... Cataract vision correction surgery . Recently, Dr. Shofner ... information during an eye exam and also online. To ... top five myths about glaucoma. , 1)    Myth: People with ...
(Date:8/27/2014)... ANS is pleased to ... anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). ... new medical therapy and will begin extending this new ... NovoTTF™ Therapy is a portable, non-invasive anti-mitotic system approved ... age and older. It is a treatment option for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The federal ... http://www.consumerinjurylawyers.com/DePuy/ ) has extended the deadline for plaintiffs to ... August 2014 Order issued by U.S. District Judge David ... to enroll in the DePuy ASR Settlement Program must ... Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – ...
(Date:8/27/2014)... August 27, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, reports ... for discovery procedures, specifically Collection and Preservation of Evidence, ... transvaginal mesh devices. (MDL No. 2187, In Re: C.R. ... United States District Court, Southern District or West Virginia; ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... , , , , ... Outstanding Debt to be Reduced by Approximately $54.8 Million , ... , Company to Book Approximately $8.2 Million Estimated ... by Approximately $45.4 Million , , , , ...
... ... been among the first to use NeoPlas Innovation,s new protocol. , ... Nashville, Tenn. (Vocus) June 16, 2009 -- With an ... his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and ...
... as Unwarranted, Withdraws Two Cold Remedy Nasal Products Citing Commitment ... June 16 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... from the U.S. Food and Drug Administration about two of ... Gel and Zicam Cold Remedy Swabs. The warning letter cited ...
... CHICAGO, June 16 David O. Barbe, M.D., a ... the Board of Trustees of the American Medical Association. , ... , , "I am honored to be elected to the ... representing physicians as the AMA and the nation focus on health-care ...
... change" says new leader of American medicine , , ... cardiologist from Bryan, Texas, was inaugurated today as the 164th ... and most influential physician organization. , , (Logo: ... In his inaugural address as AMA president, Dr. Rohack spoke ...
... Food and Drug Administration (FDA) today advised consumers to stop ... cold remedies under the Zicam(R) brand because the use of ... of smell (a condition called anosmia ). ... zinc ingredient, The Quigley Corporation (Nasdaq: QGLY ), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 4Health News:Inoperable Colon Cancer Responds to New Treatment 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3Health News:AMA Inaugurates J. James Rohack as President 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 3
... innovator of suction products in the U.S. ... and assure that their quality meets or ... and directly support our full line of ... and Poole Tip Suction handles, suction canisters, ...
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Medicine Products: